Spectinomycin

The prevention and control of gonorrhea among sexually transmitted diseases has always been an important issue in the field of public health, and spectinomycin, an aminoglycoside antibiotic, is one of the core drugs for the treatment of Neisseria gonorrhoeae infection. It exerts a bactericidal effect by acting on the 30S subunit of bacterial ribosomes to inhibit bacterial protein synthesis, and has high antibacterial activity against penicillinase-producing Neisseria gonorrhoeae. Clinically, it is mainly used for genitourinary system infections such as urethritis, cervicitis and proctitis caused by susceptible bacteria, especially for gonorrhea patients who are allergic to penicillins and cephalosporins or have drug resistance. It is the core drug of the second-line treatment regimen for gonorrhea recommended by the WHO.

At present, the global spectinomycin market size is approximately US$180 million, and the compound annual growth rate from 2023 to 2028 is expected to remain at around 3.2%. The growth momentum mainly comes from the rebound in the incidence of sexually transmitted diseases and the improvement of the primary-level sexually transmitted disease prevention and control network. In terms of the domestic market, after the implementation of centralized drug procurement for preparations, the winning bid price of spectinomycin has dropped by approximately 42%, and the overall market size is stable at RMB 230 million. The production side shows an obvious concentration feature. The domestic production capacity of active pharmaceutical ingredients accounts for 78% of the global total production capacity, making China the world's most important exporter of spectinomycin.

The original research enterprise of spectinomycin is Pfizer Inc. of the United States, with the original brand name "Trobicin". Its core compound patent expired globally in 1986. The main dosage form approved for the original research product is spectinomycin hydrochloride for injection, with a conventional specification of 2g (calculated based on spectinomycin). This product has been included in the FDA Reference Listed Drug Catalogue, and is also a variety included in the *Catalogue of Reference Preparations for Chemical Drugs* of China. At present, 12 domestic enterprises have obtained CDE registration numbers (status A) for spectinomycin hydrochloride active pharmaceutical ingredients, and another 17 enterprises have obtained marketing approval for spectinomycin hydrochloride for injection preparations, ensuring sufficient clinical supply. (Data as of September 2024, please refer to the official CDE website for the latest information.)

CATO can provide a full set of impurity reference standards for spectinomycin. All products meet the compliance requirements of multiple regulatory systems such as the Chinese Pharmacopoeia and FDA. Most of the products are in regular stock. In-stock orders placed before 16:00 can be shipped on the same day, which can fully meet the full-scenario needs of pharmaceutical enterprises for process research and development, quality research and routine quality control.